COMP <GO>
PLX vs ABBV // GROSS PROFIT MARGIN
Protalix BioTherapeutics Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PLX 0
— ABBV 11
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $2.61 (+0.77%) • MKT CAP: $210.3M
gross-margins
48.80%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PLX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PLX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 48.80% | 70.20% | -21.40 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.00% | 29.00% | -42.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.48% | 3.47% | -9.95 | ABBV | /fcf-yield <GO> |
| Operating Margin | -10.40% | 24.60% | -35.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -12.50% | 6.90% | -19.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -1.20% | 8.60% | -9.80 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 7/9 | -5.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.3 | 65.1 | -17.79 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $210.3M | $513.86B | -$513.65B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PLX REV | ABBV REV | PLX GROSS % | ABBV GROSS % | PLX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $52.7M | $61.16B | 48.8% | 70.2% | -$13.6M | $17.82B |
| FY 2024 | $53.4M | $56.33B | 54.5% | 70.0% | $7.4M | $17.83B |
| FY 2023 | $65.5M | $54.32B | — | — | -$1.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PLX // BETA —
ABBV // BETA 1.15